Acris Antibodies GmbH

Schillerstr. 5
32052 Herford
GERMANY
Phone: +49-5221-34606-0
Fax: +49-5221-34606-11
info@acris-antibodies.com

US office:
Acris Antibodies, Inc.
San Diego, CA
UNITED STATES
Phone: +1-858-888-7900
Fax: +1-858-888-7904
US-info@acris-antibodies.com

Monoclonal Antibody to CD13 - PE

Alternate names: ANPEP, APN, Alanyl aminopeptidase, Aminopeptidase M, Aminopeptidase N, Microsomal aminopeptidase, Myeloid plasma membrane glycoprotein CD13, PEPN, gp150

Catalog No.: SM1070RT

Quantity: 25 Tests

Concentration: 1.0 mg/ml

Background: CD13 is a 150kD glycoprotein expressed by granulocytes and monocytes, and by most tumour cells in cases of AML.

Uniprot ID: P15144

NCBI: NP_001141.2

GeneID: 290

Host / Isotype: Mouse / IgG1

Clone: WM15

Immunogen: Human AML cells. Spleen cells from immunised BALB/c mice were fused with cells of the mouse NS1 myeloma cell line.

Format:
State: Lyophilized purified IgG
Purification: Affinity chromatography on Protein A
Buffer System: PBS, pH7.4 containing 0.09% Sodium Azide and 1% Bovine Serum Albumin
Label: PE – R. Phycoerythrin (RPE)
Reconstitution: Restore with 1 ml distilled water

Applications:
Flow cytometry.
Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Specificity:
This antibody recognises the CD13 cell surface antigen.
Species: Human.
Other species not tested.

Storage:
Prior to and following reconstitution store the antibody at 2-8°C.
DO NOT FREEZE!
This product is photosensitive and should be protected from light.
Shelf life: one year from despatch.

General References:
1. Bradstock, K.F. et al. (1985) Human myeloid differentiation antigens identified by monoclonal antibodies: Expression on leukaemic cells. Pathology 17: 392-399.
2. Bradstock, K.F. et al. (1985) Myeloid progenitor surface antigen identified by monoclonal antibody. Br. J. Haematol. 61: 11-20.
3. Favaloro, E.J. et al. (1988) Further characterisation of myeloid antigens (gp160,95, gp150 and gp567): Investigation of epitope heterogeneity and non-haemopoietic distribution

using panels of monoclonal antibodies belonging to CD11b, CD13 and CD33. Br. J. Haematol. 69: 163-171.
4. Favaloro, E.J. (1991) CD13 (gp150, Aminopeptidase-N): Co-expression on human endothelial and haemopoietic cells, with conservation of functional activity. Immunol. Cell Biol. 69: 253-260.
5. Favaloro, E.J. et al. (1993) The hepatobiliary disease marker serum alanine-aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD13/gp150. Clin. Chim. Acta 220: 81-90.
6. Favaloro, E.J. et al. (1993) CD13 (gp150; aminopeptidase-N): Predominant functional activity in blood is localised to plasma and is not cell surface associated. Exp. Hematol. 21: 1695-1701.

Pictures:



Staining of human peripheral blood granulocytes with MOUSE ANTI HUMAN CD13:RPE